Dystonia Management

Introduction to Dystonia

• Dystonia is associated with various underlying conditions, including hypocalcemia, hypomagnesemia, and malformations of cortical development, such as polymicrogyria, focal cortical dysplasia, and periventricular nodular heterotopia, as noted by the American College of Medical Genetics and Genomics 1
• Hypocalcemia and hypomagnesemia can exacerbate each other and trigger dystonia, particularly in conditions like 22q11.2 deletion syndrome, according to the American College of Medical Genetics and Genomics 1

Diagnosis and Characteristics

• Dystonia can be triggered by sudden voluntary movements, changes in movement speed/amplitude, and emotional stress, with brief episodes (<1 minute) of dystonic movements often preceded by an aura (numbness, tingling, muscle weakness) in 78-82% of patients, as identified by the International Parkinson and Movement Disorder Society 2
• The condition is more common in males (2:1 to 4:1 ratio), typically with onset between 7-15 years, as reported by the International Parkinson and Movement Disorder Society 2
• Dystonia can be classified into different forms, including cranial dystonia, cervical dystonia, limb dystonia, and paroxysmal dyskinesias, with varying characteristics and triggers, as noted by the American Academy of Neurology 2

Treatment and Management

• Treatment options for dystonia include calcium and vitamin D supplementation for hypocalcemia, as recommended by the American College of Medical Genetics and Genomics 1, and surgical intervention for tethered cord syndrome, as suggested by the American Academy of Pediatrics 3
• Medication-induced dystonia can be treated with anticholinergic agents (e.g., benztropine) and antihistaminic medications (e.g., diphenhydramine), as reported by 4, while medication-induced akathisia can be treated with β-blockers, benzodiazepines, and lowering the dose of the causative medication 4
• Anticholinergics like trihexyphenidyl are recommended for medication-induced dystonia with strong evidence, according to the American Psychiatric Association, and have response rates of approximately 37% of idiopathic dystonia patients showing moderate to marked improvement, as noted by the American Academy of Neurology 5, 6
• Alternative treatments for dystonia when trihexyphenidyl is ineffective or poorly tolerated include benzodiazepines and deep brain stimulation, as supported by the American Academy of Neurology 6, 7
• Botulinum toxin injections are the first-line treatment for focal and segmental dystonia, providing symptom control for 3-6 months with approximately 73% improvement rate, as recommended by the American Academy of Otolaryngology-Head and Neck Surgery and American Academy of Neurology 7, 2
• Pallidal deep brain stimulation (DBS) is considered for patients when medications or botulinum toxin have failed, particularly for primary generalized or cervical dystonia, with the target being the Globus Pallidus Interna (GPi), as noted by the American Academy of Neurology 7

Rehabilitation and Lifestyle Modifications

• Patients with dystonia should be encouraged to maintain optimal postural alignment, implement graded activity to normalize movement patterns, and develop strategies to reduce muscle overactivity, pain, and fatigue, as supported by general principles of rehabilitation 7
• For patients with voice-related dystonia, adequate hydration, voice rest, use of amplification in large spaces, indoor air humidification in dry environments, and avoidance of smoking, excessive throat clearing, and drying medications are recommended, as noted by the American Academy of Otolaryngology-Head and Neck Surgery 7

Genetic and Secondary Factors

• Movement disorders, including walking dystonia, can be caused by various genetic and secondary factors, with genetic factors being the primary cause of walking dystonia, particularly mutations in genes like PRRT2, PNKD, SLC2A1, SCN8A, KCNMA1, KCNA19, and DEPDC5, as supported by the American Academy of Neurology 2
• Hereditary primary dystonias have an autosomal dominant inheritance with incomplete penetrance (60-90%), and PRRT2 gene mutations are the most common cause of paroxysmal kinesigenic dyskinesia (PKD), a common form of walking dystonia, as noted by the American Academy of Neurology 2
• Secondary causes of walking dystonia include demyelinating diseases, cerebrovascular diseases, traumatic brain injury, and lesions involving the thalamus, lenticular nucleus, globus pallidus, and internal capsule, as well as hyperthyroidism, calcium-phosphate metabolism disorders, and glucose metabolism disorders, according to the American Academy of Neurology 2

Differential Diagnosis

• Attacks of walking dystonia can present as dystonia, chorea, ballism, or combinations, with preserved consciousness during attacks, and an aura (numbness, tingling, muscle weakness) is present in 78-82% of PKD patients, with attack duration typically <1 minute for PKD, as supported by the American Academy of Neurology 2
• Duration of attacks >1 minute, age of onset over 20 years, abnormal brain imaging, no response to appropriate medications, and abnormal interictal examinations can suggest alternative diagnoses, and epilepsy, tics, hyperekplexia, Sandifer syndrome, benign paroxysmal torticollis, transient dystonia of infancy, and benign myoclonus of early infancy should be considered in the differential diagnosis of walking dystonia, as supported by the American Academy of Neurology 2